DiaCarta specializes in precision molecular diagnostics using proprietary XNA and isobDNA technologies to detect genetic alterations in cancer patients through liquid biopsy. Their tests, including RadTox™ and ColoScape™, provide sensitive and accurate monitoring of treatment responses and early detection of cancer, addressing the challenge of identifying rare genetic changes in low-volume samples.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting genetic alterations in cancer patients often struggle with sensitivity and accuracy, particularly when analyzing low-volume samples obtained through liquid biopsy. Identifying rare genetic changes, especially in early-stage cancer or for monitoring minimal residual disease (MRD), remains a significant challenge.
Solution
DiaCarta provides precision molecular diagnostics using proprietary XNA and isobDNA technologies to enhance the detection of genetic alterations in cancer patients through liquid biopsy. Their tests, such as RadTox™ and ColoScape™, offer sensitive and accurate monitoring of treatment responses and early cancer detection by addressing the challenge of identifying rare genetic changes in low-volume samples. The XNA technology boosts sensitivity and specificity in traditional platforms like Sanger sequencing, qPCR, ddPCR, and NGS, without altering existing protocols, while isobDNA™ technology amplifies signals instead of targets, eliminating the need for sample extraction and purification.
Target Audience
The primary audience includes healthcare providers, oncologists, and clinical laboratories seeking advanced diagnostic tools for cancer management, early detection, and therapy monitoring.
Features
- RadTox™ cfDNA test measures cell-free DNA levels to monitor cancer progression and therapy response, offering insights before imaging tools become available.
- ColoScape™ test detects colorectal cancer-associated mutations and methylation markers in circulating cell-free DNA from plasma samples.
- QuantiVirus™ assays for detection of SARS-CoV-2, Flu A&B, and RSV.
- QClamp® technology for single gene mutation detection.
- OptiSeq™ NGS panels for comprehensive mutation detection in colorectal and pan-cancer applications.
- iColon™ iFOB at-home test for colorectal cancer screening.
- Oncuria® multiplex immunoassay for early detection, therapy choice, and disease monitoring in bladder cancer, utilizing Luminex® xMAP technology.
- XNA technology enhances sensitivity and specificity in traditional genomic platforms.
- isobDNA™ technology amplifies signals without requiring sample extraction.